Research

At Pharnasanta Group we understand that people suffering from any disease, especially serious diseases, have specific needs and challenges associated with treatment. To meet those needs, here at Pharnasanta Group, we put forth our very best effort to offer safer medications that are even more efficient.

Our subsidiary company, NatiVita is the key element in our ability to offer these solutions. NatiVita is currently focused on developing person-specific targeted therapy for malignant tumors, the mitigation of adverse drug effects, and the treatment of socially significant diseases.

Areas of research

Engagement in drug development at the clinical testing stage, expedited registration of innovative medications

Knowledge-intensive preclinical research

Full cycle of innovative medication development

Preparation of proprietary substances for regeneration of highly efficient modern generic drugs

Caner genome research

Anticancer cell and DNA vaccines

Research Programs:

MABPOINT
Development of monoclonal antibody-based medications

Cancers:
– Lung cancer
– breast cancer
– colorectal cancer
– pancreatic cancer
– head and neck cancer
– liver cancer
– haemoblastoses.

Other diseases:
– Rheumatoid arthritis
– psoriasis
– ankylosing spondylitis
– Crohn’s disease
– multiple sclerosis

CHEMMOTION
Development of first-in-Belarus chemical generic drugs.

Cancers:
– Multiple myeloma
– lung cancer
– lymphocytic leukemia and lymphomas
– prostate cancer.

Other diseases:
– Respiratory distress syndrome
– pulmonary arterial hypertension
– growth hormone deficiency
– myocardial infarction
– multiple sclerosis